EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 38 / Numéro 1 (Janvier 2022) Med Sci (Paris), 38 1 (2022) 32-37 Références
Open Access
Numéro
Med Sci (Paris)
Volume 38, Numéro 1, Janvier 2022
Page(s) 32 - 37
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2021242
Publié en ligne 21 janvier 2022
  1. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017 ; 377 : 1119–1131. [CrossRef] [PubMed] [Google Scholar]
  2. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020; 383 : 1838–47. [CrossRef] [PubMed] [Google Scholar]
  3. Ait-Oufella H, Libby P, Tedgui A. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. Arterioscler Thromb Vasc Biol 2019 ; 39 : 1510–1519. [CrossRef] [PubMed] [Google Scholar]
  4. Bouchon A, Dietrich J, Colonna M. Cutting edge : inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000 ; 164 : 4991–4995. [CrossRef] [PubMed] [Google Scholar]
  5. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001 ; 410 : 1103–1107. [CrossRef] [PubMed] [Google Scholar]
  6. Gorlier C, Sellam J, Laurans L, et al. In familial Mediterranean fever, soluble TREM-1 plasma level is higher in case of amyloidosis. Innate Immun 2019 ; 25 : 487–490. [CrossRef] [PubMed] [Google Scholar]
  7. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006 ; 7 : 1266–1273. [CrossRef] [PubMed] [Google Scholar]
  8. Gibot S, Kolopp-Sarda MN, Bene MC, et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 2004 ; 200 : 1419–1426. [CrossRef] [PubMed] [Google Scholar]
  9. Dower K, Ellis DK, Saraf K, et al. Innate immune responses to TREM-1 activation : overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol 2008 ; 180 : 3520–3534. [CrossRef] [PubMed] [Google Scholar]
  10. Zanzinger K, Schellack C, Nausch N, Cerwenka A. Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. Immunology 2009 ; 128 : 185–195. [CrossRef] [PubMed] [Google Scholar]
  11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 ; 352 : 1685–1695. [Google Scholar]
  12. Combadiere C, Potteaux S, Rodero M, et al. Combined inhibition of CCL2, CX3CR1 and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008 ; 117 : 1649–1657. [CrossRef] [PubMed] [Google Scholar]
  13. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol 2015 ; 12 : 10–17. [CrossRef] [PubMed] [Google Scholar]
  14. Joffre J, Potteaux S, Zeboudj L, et al. Genetic and Pharmacological Inhibition of TREM-1 Limits the Development of Experimental Atherosclerosis. J Am Coll Cardiol 2016 ; 68 : 2776–2793. [CrossRef] [PubMed] [Google Scholar]
  15. Zysset D, Weber B, Rihs S, et al. TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nat Commun 2016 ; 7 : 13151. [CrossRef] [PubMed] [Google Scholar]
  16. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 2014 ; 11 : 255–265. [Google Scholar]
  17. Vinten-Johansen J.. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004 ; 61 : 481–497. [CrossRef] [PubMed] [Google Scholar]
  18. Carrasco K, Boufenzer A, Jolly L, et al. TREM-1 multimerization is essential for its activation on monocytes and neutrophils. Cell Mol Immunol 2019 ; 16 : 460–472. [CrossRef] [PubMed] [Google Scholar]
  19. Boufenzer A, Carrasco K, Jolly L, et al. Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in sepsis. Cell Mol Immunol 2021; 18 : 452–60. [CrossRef] [PubMed] [Google Scholar]
  20. Boufenzer A, Lemarie J, Simon T, et al. TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction. Circ Res 2015 ; 116 : 1772–1782. [CrossRef] [PubMed] [Google Scholar]
  21. Lemarie J, Boufenzer A, Popovic B, et al. Pharmacological inhibition of the triggering receptor expressed on myeloid cells-1 limits reperfusion injury in a porcine model of myocardial infarction. ESC Heart Fail 2015 ; 2 : 90–99. [CrossRef] [PubMed] [Google Scholar]
  22. Szigeti K, Horvath I, Veres DS, et al. A novel SPECT-based approach reveals early mechanisms of central and peripheral inflammation after cerebral ischemia. J Cereb Blood Flow Metab 2015 ; 35 : 1921–1929. [CrossRef] [PubMed] [Google Scholar]
  23. Stanley D, Mason LJ, Mackin KE, et al. Translocation and dissemination of commensal bacteria in post-stroke infection. Nat Med 2016 ; 22 : 1277–1284. [CrossRef] [PubMed] [Google Scholar]
  24. Liu Q, Johnson EM, Lam RK, et al. Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity. Nat Immunol 2019 ; 20 : 1023–1034. [CrossRef] [PubMed] [Google Scholar]
  25. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm : pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006 ; 26 : 2605–2613. [CrossRef] [PubMed] [Google Scholar]
  26. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 2011 ; 8 : 92–102. [CrossRef] [PubMed] [Google Scholar]
  27. Yuan Z, Lu Y, Wei J, et al. Abdominal Aortic Aneurysm : Roles of Inflammatory Cells. Front Immunol 2020; 11 : 609161. [Google Scholar]
  28. Vandestienne M, Zhang Y, Santos-Zas I, et al. TREM-1 orchestrates angiotensin II-induced monocyte trafficking and promotes experimental abdominal aortic aneurysm. J Clin Invest 2021; 131. [Google Scholar]
  29. Rao VH, Rai V, Stoupa S, et al. Tumor necrosis factor-alpha regulates triggering receptor expressed on myeloid cells-1-dependent matrix metalloproteinases in the carotid plaques of symptomatic patients with carotid stenosis. Atherosclerosis 2016 ; 248 : 160–169. [CrossRef] [PubMed] [Google Scholar]
  30. Vazquez CMP, Costa JO, Bomfim LGS, et al. Oxidized Low-Density Lipoprotein (Ox-LDL) and Triggering Receptor-Expressed Myeloid Cell (TREM-1) Levels Are Associated with Cardiometabolic Risk in Nonobese, Clinically Healthy, and Young Adults. Oxid Med Cell Longev 2019 ; 2019 : 7306867. [PubMed] [Google Scholar]
  31. Weber B, Schuster S, Zysset D, et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS Pathog 2014 ; 10 : e1003900. [CrossRef] [PubMed] [Google Scholar]
  32. Cuvier V, Lorch U, Witte S, et al. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. Br J Clin Pharmacol 2018 ; 84 : 2270–2279. [CrossRef] [PubMed] [Google Scholar]
  33. Francois B, Wittebole X, Ferrer R, et al. Nangibotide in patients with septic shock : a Phase 2a randomized controlled clinical trial. Intensive Care Med 2020; 46 : 1425–37. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.